“…The cysteine-less BmrCD (BmrCD-WT*)(Mishra et al, 2014), cysteine-less MsbA (MsbA-WT*)(Dong et al, 2005; Smriti et al, 2009; Zou and McHaourab, 2009), hereafter referred to as BmrCD and MsbA, and their double cysteine mutants were purified by sequential nickel affinity and size-exclusion chromatography (SEC) as previously described. Double cysteine mutants of BmrCD and MsbA were incubated with a 20-fold excess of (1-Oxyl-2,2,5,5-tetramethylpyrroline-3-methyl) methanethiosulfonate (MTSSL, Enzo Life Sciences) for 4 h at 23 °C and placed on ice for ~12 h. The labeled proteins were then separated from free label by SEC on a Superdex 200 column equilibrated with respective SEC buffer.…”